Overview Phase 1 Study of Pemigatinib in Patients With Advanced Malignancies With FGF/FGFR Alterations Status: Completed Trial end date: 2021-03-08 Target enrollment: Participant gender: Summary This is a phase 1 study to investigate the characteristics of PK, PD and safety in subjects with advanced malignancies with FGF/FGFR alterations. Phase: Phase 1 Details Lead Sponsor: Innovent Biologics (Suzhou) Co. Ltd.